1. Sexually Transmitted Disease Surveillance 2011 Division of STD Prevention

2. Gonorrhea—Rates, United States, 1941–2011 2011-Fig 16. SR

3. Gonorrhea—Rates by Sex, United States, 1991–2011 2011-Fig 17. SR

4. Gonorrhea—Rates by Region, United States, 2002–2011 2011-Fig 18. SR

5. Gonorrhea—Rates by State, United States and Outlying areas, 2011 NOTE: The total rate of gonorrhea for the United States and outlying area (Guam, Puerto Rico, and Virgin Islands) was 103.1 per 100,000 population. 2011-Fig 19. SR

6. Gonorrhea—Rates by County, United States, 2011 2011-Fig 20. SR

7. Gonorrhea—Rates by Age and Sex, United States, 2011 2011-Fig 21. SR

8. Gonorrhea—Rates by Age Among Women Aged 15–44 Years, United States, 2002–2011 2011-Fig 22. SR

9. Gonorrhea—Rates by Age Among Men Aged 15–44 Years, United States, 2002–2011 2011-Fig 23. SR

10. Gonorrhea—Rates by Race/Ethnicity, United States, 2002–2011 2011-Fig 24. SR

11. Gonorrhea—Cases by Reporting Source and Sex, United States, 2002–2011 2011-Fig 25. SR

12. Gonorrhea—Percentage of Reported Cases by Sex and Selected Reporting Sources, United States, 2011 *HMO=health maintenance organization; HD=health department NOTE: These categories represent 66.5% of cases with a known reporting source. Of all cases, 11.7% has a missing or unknown reporting source. 2011-Fig 26. SR

13. Proportion MSM*, MSW*, and Women Among Interviewed † Gonorrhea Cases by Site, STD Surveillance Network (SSuN), 2011 *MSM=men who have sex with men; MSW=men who have sex with women only. †SSuN interviews conducted in a randomly selected sample of the patient population with gonorrhea (n=4,540). ‡California data excludes San Francisco. NOTE: See Appendix for included jurisdictions within each state. 2011-Fig 27. SR

14. Gonorrhea—Positivity Among Women Aged 15–24 Years Tested in Family Planning Clinics, by State, Infertility Prevention Project, United States and Outlying Areas, 2011 *States/areas had incomplete data or reported gonorrhea positivity data on fewer than 500 women aged 15-24 years in 2011. 2011-Fig 28. SR

15. Location of Participating Sentinel Sites and Regional Laboratories, Gonococcal Isolate Surveillance Project (GISP), United States, 2011 *NOTE: The Austin site is a regional laboratory only. 2011-Fig 29. SR

16. Distribution of Minimum Inhibitory Concentrations (MICs) of Ceftriaxone Among Neisseria gonorrhoeae Isolates, Gonococcal Isolate Surveillance Project (GISP), 2007–2011 2011-Fig 30. SR

17. Distribution of Minimum Inhibitory Concentrations (MICs) of Cefixime Among Neisseria gonorrhoeae Isolates, Gonococcal Isolate Surveillance Project (GISP), 2009–2011 NOTE: Isolates were not tested for cefixime susceptibility in 2007 and 2008 2011-Fig 31. SR

18. Distribution of Minimum Inhibitory Concentrations (MICs) of Azithromycin Among Neisseria gonorrhoeae Isolates, Gonococcal Isolate Surveillance Project (GISP), 2007–2011 2011-Fig 32. SR

19. Percentage of Neisseria gonorrhoeae Isolates that are Ciprofloxacin-Resistant by Sex of Sex Partner, Gonococcal Isolate Surveillance Project (GISP), 1995–2011 *MSM=men who have sex with men; MSW=men who have sex with women only. 2011-Fig 33. SR

20. Penicillin, Tetracycline, and Ciprofloxacin Resistance Among Neisseria gonorrhoeae Isolates, Gonococcal Isolate Surveillance Project (GISP), 2011 NOTE: PenR = penicillinase producing Neisseria gonorrhoeae and chromosomally mediated penicillin-resistant N. gonorrhoeae; TetR = chromosomally and plasmid mediated tetracycline-resistant N. gonorrhoeae; and QRNG = quinolone-resistant N. gonorrhoeae. 2011-Fig 34. SR

21. Antimicrobial Drugs Used to Treat Gonorrhea Among Participants, Gonococcal Isolate Surveillance Project (GISP), 1988–2011 NOTE: For 2011, “Other” includes no therapy (1.2%), azithromycin 2g (2.3%), and other less frequently used drugs. 2011-Fig 35. SR